Pfanstiehl, Inc.
Trevor Calkins is an accomplished professional in the field of chemistry and organic synthesis, currently serving as Chief Technical Officer and Vice President of Research and Development at Pfanstiehl, Inc. since March 2015. Prior experience includes roles as Director of Process Development at SAFC Pharma/Sigma-Aldrich from 2005 to March 2015, Scientist at Eisai Research Institute from March 1999 to May 2005, and Senior Scientist at Microcide Pharmaceuticals from September 1996 to March 1999. Trevor Calkins holds a BA in Chemistry from Cornell College, a Ph.D. in Organic Synthesis from the University of Utah, and completed a postdoctoral fellowship in Organic Synthesis at Stanford University.
This person is not in any teams
This person is not in any offices
Pfanstiehl, Inc.
1 followers
Founded in 1919 by Carl A. Pfanstiehl, our company specializes in isolation, purification, custom synthesis and scale-up development of cGMP, high purity and low endotoxin (HPLE) Injectable Formulation Components, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API’s), in gram to multi-ton commercial quantities. Tried and true parenteral excipients include trehalose, sucrose, mannitol, maltose, sorbitol, and hydroxypropyl betacyclodextrin. Upstream, high purity media components include animal component free galactose, mannose, and L-arginine. At Pfanstiehl we pride ourselves on being customer focused and are amenable to producing cGMP components on a custom basis to solve formulation challenges for our clients.